Skip to main content
Comprehensive review of the management of knee osteoarthritis - topicals, analgesics, narcotics, intraarticular, metabo

Dr. John Cush RheumNow

6 months 4 weeks ago
Comprehensive review of the management of knee osteoarthritis - topicals, analgesics, narcotics, intraarticular, metabolic, nutraceuticals, TENS, acupuncture and biologics. https://t.co/3UjPQeZut9 https://t.co/z0dzENSbtX
SMART study - Single vs. Split Dose Methotrexate in RA

Split dose weekly, oral methotrexate (MTX) was shown to be supe

Dr. John Cush RheumNow

6 months 4 weeks ago
SMART study - Single vs. Split Dose Methotrexate in RA Split dose weekly, oral methotrexate (MTX) was shown to be superior to single dose MTX in treating active rheumatoid arthritis (RA) patients. https://t.co/JN5wPGNjao https://t.co/hI8dxWmZe8
APP Pearls “When I’m explaining treatment options, I say “hey you are the captain of this ship, I’m your co-capt

Dr. John Cush RheumNow

6 months 4 weeks ago

APP Pearls “When I’m explaining treatment options, I say “hey you are the captain of this ship, I’m your co-captain. I help to guide you along this journey… (I can help you) avoid that Hurricane.” - April Woodrow, APRN, ANP-BC

Editor's note: This article was originally published April 22, 2025, and is being shared again as part of RheumNow's 'Best of 2025' series as we close out the year. Enjoy!
Best of 2025: Glossary for Giant Cell Arteritis

Dejaco and colleagues have published a glossary of terms often used in

Dr. John Cush RheumNow

7 months ago
Best of 2025: Glossary for Giant Cell Arteritis Dejaco and colleagues have published a glossary of terms often used in conjunction with giant cell arteritis. The glossary of definitions for 23 signs and symptoms of GCA was developed through a consensus process involving https://t.co/yfJXZx5r6G
Best of 2025: Glucocorticoids in SLE: how to start, how to follow, how to stop

70+ years after their debut, glucocorti

Dr. John Cush RheumNow

7 months ago
Best of 2025: Glucocorticoids in SLE: how to start, how to follow, how to stop 70+ years after their debut, glucocorticoids remain a fast, powerful tool for SLE—but long-term toxicity comes at a high cost. Guidelines now favor GC “bridging therapy”: use briefly, taper fast. The https://t.co/RS0JQquv6j
APP Pearls “Steroids are not a long-term plan; AND One visit cannot fix everything” - Claudia Rivera-Salas, NP

Dr. John Cush RheumNow

7 months ago
APP Pearls “Steroids are not a long-term plan; AND One visit cannot fix everything” - Claudia Rivera-Salas, NP
2025 update of EULAR recommendations on lupus nephritis

At the 2025 EULAR congress in Barcelona, Prof Dimitrios Boumpa

Dr. John Cush RheumNow

7 months ago
2025 update of EULAR recommendations on lupus nephritis At the 2025 EULAR congress in Barcelona, Prof Dimitrios Boumpas presented updated EULAR recommendations on managing lupus nephritis (LN). The key change is that the historic standard of care (mycophenolate with https://t.co/78J1L80Zxe
Best of 2025: Distinguishing Septic and Gouty Arthritis

A single center, retrospective review of patients undergoing k

Dr. John Cush RheumNow

7 months ago
Best of 2025: Distinguishing Septic and Gouty Arthritis A single center, retrospective review of patients undergoing knee joint fluid aspirations for presumed crystalline arthritis (CA) showed that synovial WBC may provide a useful diagnostic marker for SA with an optimal https://t.co/G31CazbqmR
More effective treatments in patients with rheumatic diseases have resulted in less need for major surgery, yet a substantial number of RMD patients will undergo surgery often in the setting of DMARDs use. A scoping review looked at numerous clinical practice guidelines/recommendations for the perioperative management of DMARDs and found inconsistencies and low quality evidence, with great reliance on conditional (expert opinion) recommendations.
The European Respiratory Society (ERS) and European Alliance of Associations for Rheumatology (EULAR) have published clinical practice guidelines for the evaluation and management of connective tissue diseases (CTD) associated interstitial lung disease (ILD) in two simultaneous publications in the European Respiratory Journal and Annals of Rheumatic Diseases.
Novartis announced top line results of its ianalumab (VAY736;B cell inhibitor) in primary Sjögren’s dz. 2 RCTs, NEPTU

Dr. John Cush RheumNow

7 months ago
Novartis announced top line results of its ianalumab (VAY736;B cell inhibitor) in primary Sjögren’s dz. 2 RCTs, NEPTUNUS-1 and NEPTUNUS-2, met met primary endpoints w/ statistically significant improvements in disease activity in Sjögren’s patients. https://t.co/cIBhF3YJh3 https://t.co/RpZGe0Sa0K
Hydroxychloroquine for Everyone

Nearly 25 years ago, while lecturing on best therapies for rheumatoid arthritis (RA),

Dr. John Cush RheumNow

7 months ago
Hydroxychloroquine for Everyone Nearly 25 years ago, while lecturing on best therapies for rheumatoid arthritis (RA), I loudly stated that hydroxychloroquine was “useless” and, deservedly, I was “boo-ed” off stage. My point then was that rheumatologists needed to be aggressive, https://t.co/rlnogTqk49
×